STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Oct. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

The components of stock-based compensation expense recognized in the condensed consolidated statements of operations consisted of the following (in thousands):

	Three Months Ended October 31,				Nine Months Ended October 31,
	2025		2024		2025		2024
Cost of revenue	$	5,644	$	5,810	$	15,708	$	16,243
Research and development	24,952		22,816		70,182		61,092
Sales and marketing	22,483		18,612		66,736		55,568
General and administrative	22,809		22,950		65,837		60,515
Restructuring	(547)		—		(583)		—
Total	$	75,341	$	70,188	$	217,880	$	193,418

Schedule of Restricted Stock Units

A summary of our RSU activity is as follows:

	Number of RSUs	Weighted-Average Grant Date Fair Value
Outstanding as of January 31, 2025	27,357,828	$	21.60
Granted	21,447,547	18.25
Released	(8,740,428)	21.95
Forfeited	(5,543,589)	20.29
Outstanding as of October 31, 2025	34,521,358	$	19.64

Schedule of Performance Stock Units

A summary of our PSU activity is as follows:

	Number of PSUs	Weighted-Average Grant Date Fair Value
Outstanding as of January 31, 2025	233,680	$	22.27
Granted	1,464,871	17.19
Released	(224,323)	22.26
Forfeited	(98,529)	17.85
Outstanding as of October 31, 2025	1,375,699	$	17.18

Schedule of Stock Options

A summary of our stock option activity is as follows:

	Number of Options	Weighted-Average Exercise Price
Outstanding as of January 31, 2025	13,164,743	$	6.31
Assumed options from Prompt acquisition	415,109	0.21
Exercised	(3,537,247)	4.70
Forfeited	(43,131)	2.10
Outstanding as of October 31, 2025	9,999,474	$	6.64
Vested and expected to vest as of October 31, 2025	9,999,474	$	6.64
Vested and exercisable as of October 31, 2025	7,794,591	$	6.32

Schedule of Restricted Common Stock

Restricted common stock is included in issued and outstanding shares as they are legally issued and outstanding, but are not deemed outstanding for accounting purposes until the shares vest. A summary of our restricted common stock activity is as follows:

	Number of Shares	Weighted-Average Grant Date Fair Value
Outstanding as of January 31, 2025	1,497,212	$	27.49
Granted	3,108,988	19.10
Vested	(749,158)	27.48
Unvested balance as of October 31, 2025	3,857,042	$	20.73